# Topical Romidepsin to Treat Early-Stage Cutaneous T-Cell Lymphoma

> **NCT01445340** · PHASE1 · TERMINATED · sponsor: **National Cancer Institute (NCI)** · enrollment: 6 (actual)

## Conditions studied

- Mycosis Fungoides
- Cutaneous T-Cell Lymphoma
- Neoplasms

## Interventions

- **DRUG:** Romidepsin (FR901228)

## Key facts

- **NCT ID:** NCT01445340
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-04-21
- **Primary completion:** —
- **Final completion:** 2012-06-29
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2019-12-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01445340

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01445340, "Topical Romidepsin to Treat Early-Stage Cutaneous T-Cell Lymphoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01445340. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*